Antibodies to Epstein-Barr Virus in Burkitt's Lymphoma and Control Groups2

PLoS ONE ◽  
2017 ◽  
Vol 12 (10) ◽  
pp. e0186614 ◽  
Author(s):  
Marc Jordi ◽  
Jeannine Marty ◽  
Vanessa Mordasini ◽  
Anna Lünemann ◽  
Scott McComb ◽  
...  

Cell ◽  
1981 ◽  
Vol 24 (2) ◽  
pp. 543-553 ◽  
Author(s):  
Duncan K. Fischer ◽  
George Miller ◽  
Lyn Gradoville ◽  
Lee Heston ◽  
Marien W. Weststrate ◽  
...  

1979 ◽  
Vol 24 (5) ◽  
pp. 567-571 ◽  
Author(s):  
David J. Granlund ◽  
Francis Nkrumah ◽  
I. Virginia Perkins ◽  
Robert J. Biggar ◽  
Paul H. Levine ◽  
...  

1999 ◽  
Vol 73 (12) ◽  
pp. 9827-9831 ◽  
Author(s):  
Jun Komano ◽  
Seiji Maruo ◽  
Koichi Kurozumi ◽  
Takanori Oda ◽  
Kenzo Takada

ABSTRACT Our previous reports indicated that Epstein-Barr virus (EBV) contributes to the malignant phenotype and resistance to apoptosis in Burkitt’s lymphoma (BL) cell line Akata (N. Shimizu, A. Tanabe-Tochikura, Y. Kuroiwa, and K. Takada, J. Virol. 68:6069–6073, 1994; J. Komano, M. Sugiura, and K. Takada, J. Virol. 72:9150–9156, 1998). Here we report that the EBV-encoded small RNAs (EBERs) are responsible for these phenotypes. Transfection of the EBER genes into EBV-negative Akata clones restored the capacity for growth in soft agar, tumorigenicity in SCID mice, resistance to apoptotic inducers, and upregulated expression of bcl-2 oncoprotein that were originally retained in parental EBV-positive Akata cells and lost in EBV-negative subclones. This is the first report which provides evidence that virus-encoded RNAs (EBERs) have oncogenic functions in BL cells.


Sign in / Sign up

Export Citation Format

Share Document